<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2009</study_start_year><data_sharing_plan>IPD Sharing (as of February 2022): No</data_sharing_plan><condition>Ovarian Cancer</condition><condition>Kidney Neoplasms</condition><condition>Gliomas</condition><condition>Head and Neck Cancer</condition><condition>Non-small Cell Lung Cancer</condition><condition>Colorectal Cancer</condition><condition>Esophageal Cancer</condition><condition>Pancreatic Cancer</condition><condition>Kidney Cancer</condition><condition>Breast Cancer</condition><disease>Ovarian Cancer</disease><disease>Kidney Neoplasms</disease><disease>Gliomas</disease><disease>Non-small Cell Lung Cancer</disease><disease>Colorectal Cancer</disease><disease>Esophageal Cancer</disease><disease>Head And Neck Cancer</disease><disease>Pancreatic Cancer</disease><disease>Kidney Cancer</disease><disease>Breast Cancer</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2077295</full_dataset_link><location>United States</location><study_start_month>7</study_start_month><repository>ECRIN MDR</repository><study_status>Completed</study_status></additional><is_claimable>false</is_claimable><name>177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors</name><description>The purpose of this study is to evaluate changes in tumor blood flow and disease response to the investigation agent, 177Lu-J591.</description><dates><creation>2009-07-15</creation></dates><accession>2077295</accession><cross_references><ClinicalTrials___gov>NCT00967577</ClinicalTrials___gov></cross_references></HashMap>